«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:

期数:

2024年04期

页码:

543-547

栏目:

论著

出版日期:

2024-08-25

文章信息/Info

Title:

Prognostic significance of SNHG17 overexpression for non-small cell lung cancer resection

作者:

韩晓宇¹; 李柯育¹; 赵志菲¹; 高建平²

100085 北京,中国人民解放军总医院第二医学中心肿瘤内科¹
102600 北京,首都医科大学大兴教学医院胸外科²

Author(s):

Han Xiaoyu¹;  Li Keyu¹;  Zhao Zhifei¹;  Gao Jianping².

¹Department of Medical Oncology, Second Medical Center, General Hospital of the Chinese People's Liberation Army, Beijing 100085, China; ²Department of Thoracic Surgery, Daxing Teaching Hospital, Capital Medical University, Beijing 102600, China

关键词:

非小细胞肺癌;  小核仁RNA宿主基因17;  手术切除;  预后

Keywords:

Non-small cell lung cancer;  Small nucleolar RNA host gene 17;  Surgical excision;  Prognosis

分类号:

R734.2

DOI:

10.3877/cma.j.issn.1674-6902.2024.04.007

摘要:

目的 分析长链非编码RNA小核仁RNA宿主基因17(small nucleolar RNA host gene 17, SNHG17)表达对非小细胞肺癌(non-small cell lung cancer, NSCLC)切除预后的意义。方法 选择2020年1月至2022年6月我院收治行NSCLC根治性手术87例患者为对象。术后随访,记录无复发生存期(recurrence-free survival, RFS)和总生存期(overall survival, OS)。采用实时荧光定量PCR法检测组织SNHG17表达水平。结果 NSCLC组织SNHG17表达(1.85±0.61)高于癌旁正常组织(1.03±0.36)(P<0.05)。TNM分期Ⅰ期SNHG17表达(1.52±0.25),Ⅱ期(1.83±0.66)(t=2.283,P<0.05)、Ⅲ期组织SNHG17表达(2.28±0.58)(t=6.058,P<0.05),Ⅲ期SNHG17表达较Ⅱ期上调(P<0.05)。SNHG17高表达(≥1.72)43例,SNHG17低表达(<1.72)44例,NSCLC组织SNHG17表达与TNM分期有关(P<0.05)。随访期间复发43例(49.43%),死亡33例(37.93%)。与SNHG17低表达无复发33例(75.00%)相比,SNHG17高表达者无复发11例(25.58%)少,SNHG17低表达中位RFS时间4.30年长于高表达者2.40年( P<0.05); SNHG17低表达生存35例(79.55%)大于高表达者19例( 44.19%),SNHG17低表达中位OS时间5.11年长于高表达者 4.28年( P<0.05)。COX回归分析显示SNHG17高表达是NSCLC切除术后复发和预后风险的预测因子(P<0.05)。结论 SNHG17在NSCLC组织中呈高表达,与NSCLC切除复发和预后高风险密切相关。SNHG17有望作为预测手术切除NSCLC预后的生物标志物。

Abstract:

Objective To analyze the prognostic significance of long non-coding RNA small nucleolar RNA host gene 17(SNHG17)expression in non-small cell lung cancer(NSCLC)resection. Methods A total of 87 patients with NSCLC undergoing radical surgery in our hospital from January 2020 to June 2022 were selected as the subjects. After the operation, recurrence-free survival(RFS)and overall survival(OS)were recorded. The expression level of SNHG17 was detected by real-time fluorescence quantitative PCR. Results The expression of SNHG17 in NSCLC tissues(1.85±0.61)was higher than that in adjacent normal tissues(1.03±0.36)(P<0.05). TNM stage Ⅰ SNHG17 expression(1.52±0.25), stage Ⅱ(1.83±0.66)(t=2.283, P<0.05), stage Ⅲ SNHG17 expression(2.28±0.58)(t=6.058, P<0.05). The expression of SNHG17 in stage Ⅲ was higher than that in stage Ⅱ(P<0.05). There were 43 cases with high SNHG17 expression(≥1.72)and 44 cases with low SNHG17 expression(<1.72). The expression of SNHG17 in NSCLC tissues was correlated with TNM stage(P<0.05). During the follow-up period, 43 cases(49.43%)relapsed and 33 cases(37.93%)died. Compared with 33 cases(75.00%)with low expression of SNHG17, 11 cases(25.58%)with high expression of SNHG17 had no recurrence, and the median RFS time of low expression of SNHG17 was 4.30 years longer than that of high expression of SNHG17 2.40 years(P<0.05). The survival rate of 35 patients(79.55%)with low expression of SNHG17 was higher than that of 19 patients(44.19%)with high expression. The median OS time of low expression of SNHG17 was 5.11 years longer than that of high expression 4.28 years)(P<0.05). COX regression analysis showed that high expression of SNHG17 was a predictor of recurrence and death after NSCLC resection(P<0.05). Conclusion SNHG17 is highly expressed in NSCLC tissues, and high expression is closely related to the risk of recurrence and death of NSCLC. SNHG17 is a promising biomarker for predicting the prognosis of surgically resected NSCLC.

参考文献/References:

1 Leiter A, Veluswamy RR, Wisnivesky JP. The global burden of lung cancer: current status and future trends[J]. Nature Reviews Clinical Oncology, 2023, 20(9): 624-639.
2 Chen P, Liu Y, Wen Y, Zhou C. Non-small cell lung cancer in China[J]. Cancer Commun(Lond), 2022, 42(10): 937-970.
3 Montagne F, Guisier F, Venissac N, et al. The role of surgery in lung cancer treatment: present indications and future perspectives-state of the art[J]. Cancers, 2021, 13(15): 3711-3733.
4 Li N, Wang BX, Li J, et al. Perioperative circulating tumor DNA as a potential prognostic marker for operable stage Ⅰ to ⅢA non-small cell lung cancer[J]. Cancer, 2022, 128(4): 708-718.
5 Cao Z, Oyang L, Luo X, et al. The roles of long non-coding RNAs in lung cancer[J]. Journal of cancer, 2022, 13(1): 174-183.
6 赵 效, 张冰海, 李晓霞, 等. 长链非编码RNA与非小细胞肺癌相关性的研究进展[J]. 国际生物医学工程杂志, 2021, 44(1): 60-64.
7 Ghahramani Almanghadim H, Ghorbian S, Khademi NS, et al. New insights into the importance of long non-coding RNAs in lung cancer: future clinical approaches[J]. DNA and Cell Biology, 2021, 40(12): 1476-1494.
8 Entezari M, Ghanbarirad M, Taheriazam A, et al. Long non-coding RNAs and exosomal lncRNAs: Potential functions in lung cancer progression, drug resistance and tumor microenvironment remodeling[J]. Biomed Pharmacother, 2022, 150: 112963.
9 李 渊, 王欣鑫, 陈世勇, 等. 小核仁RNA宿主基因17在癌症进展中的作用研究进展[J]. 解放军医学杂志, 2022, 47(9): 932-940.
10 Akbari A, Abbasi S, Borumandnia N, et al. Epigenetic regulation of gastrointestinal cancers mediated by long non-coding RNAs[J]. Cancer Biomark, 2022, 35(4): 359-377.
11 Ma L, Gao J, Zhang N, et al. Long noncoding RNA SNHG17: a novel molecule in human cancers[J]. Cancer Cell Int. 2022, 22(1): 104-115.
12 Cao S, Li H, Li L. LncRNA SNHG17 contributes to the progression of cervical cancer by targeting microRNA-375-3p[J]. Cancer Manag Res, 2021, 13: 4969-4978.
13 Zhu XM, Li L, Ren LL, et al. LncRNA SNHG17 predicts poor prognosis and promotes cell proliferation and migration in hepatocellular carcinoma[J]. Eur Rev Med Pharmacol Sci, 2021, 25(12): 4219-4227.
14 Chen W, Wang L, Li X, et al. LncRNA SNHG17 regulates cell proliferation and invasion by targeting miR-338-3p/SOX4 axis in esophageal squamous cell carcinoma[J]. Cell Death Dis, 2021, 12(9): 806-814.
15 Tang Z, Feng H, Shu L, et al. Identification of two novel lipid metabolism-related long non-coding RNAs(SNHG17 and LINC00837)as potential signatures for osteosarcoma prognosis and precise treatment[J]. BMC Med Genomics, 2023, 16(1): 115-127.
16 Kay FU, Kandathil A, Batra K, et al. Revisions to the Tumor, Node, Metastasis staging of lung cancer(8 edition): Rationale, radiologic findings and clinical implications[J]. World J Radiol, 2017, 9(6): 269-279.
17 Chevallier M, Borgeaud M, Addeo A, et al. Oncogenic driver mutations in non-small cell lung cancer: Past, present and future[J]. World J Clin Oncol, 2021, 12(4): 217-238.
18 Fois SS, Paliogiannis P, Zinellu A, et al. Molecular epidemiology of the main druggable genetic alterations in non-small cell lung cancer[J]. Int J Mol Sci, 2021, 22(2): 612-630.
19 García-Padilla C, Dueñas Á, García-López V, et al. Molecular mechanisms of lncRNAs in the dependent regulation of cancer and their potential therapeutic use[J]. Int J Mol Sci, 2022, 23(2): 764-784.
20 Luo Y, Lin J, Zhang J, et al. LncRNA SNHG17 contributes to proliferation, migration, and poor prognosis of hepatocellular carcinoma[J]. Can J Gastroenterol Hepatol, 2021, 2021(1): 9990338.
21 Ma T, Zhou X, Wei H, et al. Long non-coding RNA SNHG17 upregulates RFX1 by sponging miR-3180-3p and promotes cellular function in hepatocellular carcinoma[J]. Front Genet, 2021, 11: 607636.
22 Shen S, Liang J, Liang X, et al. SNHG17, as an EMT-related lncRNA, promotes the expression of c-Myc by binding to c-Jun in esophageal squamous cell carcinoma[J]. Cancer Sci, 2022, 113(1): 319-333.
23 Yang Z, Jiang Y, Wang L, et al. Prognosis and biological function of SGOL1 in clear cell renal cell carcinoma: a multiomics analysis[J]. BMC Med Genomics, 2024, 17(1): 60-80.
24 Wu J, Dong G, Liu T, et al. LncRNA SNHG17 promotes tumor progression and predicts poor survival in human renal cell carcinoma via sponging miR-328-3p[J]. Aging(Albany NY), 2021, 13(17): 21232-21250.
25 Zhang Z, Yan Y, Zhang B, et al. Long non-coding RNA SNHG17 promotes lung adenocarcinoma progression by targeting the microRNA-193a-5p/NETO2 axis[J]. Oncol Lett, 2021, 22(6): 818-829.
26 Zhang H, Wang SQ, Wang L, et al. m6A methyltransferase METTL3-induced lncRNA SNHG17 promotes lung adenocarcinoma gefitinib resistance by epigenetically repressing LATS2 expression[J]. Cell Death Dis, 2022, 13(7): 657-669.
27 Bian Z, Zhou M, Cui K, et al. SNHG17 promotes colorectal tumorigenesis and metastasis via regulating Trim23-PES1 axis and miR-339-5p-FOSL2-SNHG17 positive feedback loop[J]. J Exp Clin Cancer Res, 2021, 40(1): 360-372.
28 Zhao H, Dong H, Wang P, et al. Long non-coding RNA SNHG17 enhances the aggressiveness of C4-2 human prostate cancer cells in association with β-catenin signaling[J]. Oncol Lett, 2021, 21(6): 472-481.

备注/Memo

备注/Memo:

基金项目: 首都卫生发展科研专项项目(首发2020-4-2085)
通信作者: 高建平, Email: 2213144876@qq.com

常用功能

更新日期/Last Update: 2024-08-25